Clinical Trial

SmartGlass-Guided ERCP with Cannulation of Native Papilla 1.0

Study acronym: EmeRald
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this prospective randomized study is to evaluate whether telemedical assistance via SmartGlasses is equivalent to physical presence in teaching Endoscopic Retrograde Cholangiopancreaticography (ERCP) in terms of examination success and safety. Endoscopic papilla cannulation is a key skill for successful ERCP and therefore a measurable primary endpoint of the study. This can be measured as the time (in seconds/minutes) between stable visualization of the papilla and successful endoscopic cannulation of the target structure (bile duct or pancreatic duct).
Trial Details
NCT Number NCT06683716
Lead Sponsor Helios Kliniken Schwerin
Conditions Biliary Tract Diseases, Pancreatic Diseases
Enrollment 170 participants
Start Date 2025-01-02
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-12